spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Helsinn Healthcare 

 HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Sep 2009
New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2009
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Nov 2008
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2008
FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2007
MGI PHARMA and HELSINN Announce Submission of Supplemental New Drug Application for Aloxi(R) Capsules
Biopharmaceuticals
 HSMN NewsFeed - 4 Sep 2007
MGI PHARMA and HELSINN Announce Aloxi(R) sNDA Approval Allowing for Repeated Dosing for Cancer Patients Receiving Multiple Day Chemotherapy Regimens
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2007
MGI PHARMA and HELSINN Announce Submission of Supplemental New Drug Application for Aloxi(R) Injection in Post-Operative Nausea and Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2007
MGI PHARMA and HELSINN HEALTHCARE SA Announce Patent Extension for Aloxi(R) Injection
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2006
MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi(R) (Palonosetron Hydrochloride) Injection for the Prevention of Post Operative Nausea & Vomiting
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2006
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
EKR Therapeutics Acquires Exclusive License for Gelclair(R) from Helsinn Healthcare SA
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Jun 2006
Exelixis Appoints Experienced Biotechnology Executive as Chief Medical Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
Helsinn Healthcare
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.